Cargando…
Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells
Treatment for the lethal primary adult brain tumor glioblastoma (GBM) includes the chemotherapy temozolomide (TMZ), but TMZ resistance is common and correlates with promoter methylation of the DNA repair enzyme O-6-methylguanine-DNA methyltransferase (MGMT). To improve treatment of GBMs, including t...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096095/ https://www.ncbi.nlm.nih.gov/pubmed/33945569 http://dx.doi.org/10.1371/journal.pone.0250649 |
_version_ | 1783688095078547456 |
---|---|
author | Williford, Sarah E. Libby, Catherine J. Ayokanmbi, Adetokunbo Otamias, Arphaxad Gordillo, Juan J. Gordon, Emily R. Cooper, Sara J. Redmann, Matthew Li, Yanjie Griguer, Corinne Zhang, Jianhua Napierala, Marek Ananthan, Subramaniam Hjelmeland, Anita B. |
author_facet | Williford, Sarah E. Libby, Catherine J. Ayokanmbi, Adetokunbo Otamias, Arphaxad Gordillo, Juan J. Gordon, Emily R. Cooper, Sara J. Redmann, Matthew Li, Yanjie Griguer, Corinne Zhang, Jianhua Napierala, Marek Ananthan, Subramaniam Hjelmeland, Anita B. |
author_sort | Williford, Sarah E. |
collection | PubMed |
description | Treatment for the lethal primary adult brain tumor glioblastoma (GBM) includes the chemotherapy temozolomide (TMZ), but TMZ resistance is common and correlates with promoter methylation of the DNA repair enzyme O-6-methylguanine-DNA methyltransferase (MGMT). To improve treatment of GBMs, including those resistant to TMZ, we explored the potential of targeting dopamine receptor signaling. We found that dopamine receptor 3 (DRD3) is expressed in GBM and is also a previously unexplored target for therapy. We identified novel antagonists of DRD3 that decreased the growth of GBM xenograft-derived neurosphere cultures with minimal toxicity against human astrocytes and/or induced pluripotent stem cell-derived neurons. Among a set of DRD3 antagonists, we identified two compounds, SRI-21979 and SRI-30052, that were brain penetrant and displayed a favorable therapeutic window analysis of The Cancer Genome Atlas data demonstrated that higher levels of DRD3 (but not DRD2 or DRD4) were associated with worse prognosis in primary, MGMT unmethylated tumors. These data suggested that DRD3 antagonists may remain efficacious in TMZ-resistant GBMs. Indeed, SRI-21979, but not haloperidol, significantly reduced the growth of TMZ-resistant GBM cells. Together our data suggest that DRD3 antagonist-based therapies may provide a novel therapeutic option for the treatment of GBM. |
format | Online Article Text |
id | pubmed-8096095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-80960952021-05-17 Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells Williford, Sarah E. Libby, Catherine J. Ayokanmbi, Adetokunbo Otamias, Arphaxad Gordillo, Juan J. Gordon, Emily R. Cooper, Sara J. Redmann, Matthew Li, Yanjie Griguer, Corinne Zhang, Jianhua Napierala, Marek Ananthan, Subramaniam Hjelmeland, Anita B. PLoS One Research Article Treatment for the lethal primary adult brain tumor glioblastoma (GBM) includes the chemotherapy temozolomide (TMZ), but TMZ resistance is common and correlates with promoter methylation of the DNA repair enzyme O-6-methylguanine-DNA methyltransferase (MGMT). To improve treatment of GBMs, including those resistant to TMZ, we explored the potential of targeting dopamine receptor signaling. We found that dopamine receptor 3 (DRD3) is expressed in GBM and is also a previously unexplored target for therapy. We identified novel antagonists of DRD3 that decreased the growth of GBM xenograft-derived neurosphere cultures with minimal toxicity against human astrocytes and/or induced pluripotent stem cell-derived neurons. Among a set of DRD3 antagonists, we identified two compounds, SRI-21979 and SRI-30052, that were brain penetrant and displayed a favorable therapeutic window analysis of The Cancer Genome Atlas data demonstrated that higher levels of DRD3 (but not DRD2 or DRD4) were associated with worse prognosis in primary, MGMT unmethylated tumors. These data suggested that DRD3 antagonists may remain efficacious in TMZ-resistant GBMs. Indeed, SRI-21979, but not haloperidol, significantly reduced the growth of TMZ-resistant GBM cells. Together our data suggest that DRD3 antagonist-based therapies may provide a novel therapeutic option for the treatment of GBM. Public Library of Science 2021-05-04 /pmc/articles/PMC8096095/ /pubmed/33945569 http://dx.doi.org/10.1371/journal.pone.0250649 Text en © 2021 Williford et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Williford, Sarah E. Libby, Catherine J. Ayokanmbi, Adetokunbo Otamias, Arphaxad Gordillo, Juan J. Gordon, Emily R. Cooper, Sara J. Redmann, Matthew Li, Yanjie Griguer, Corinne Zhang, Jianhua Napierala, Marek Ananthan, Subramaniam Hjelmeland, Anita B. Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells |
title | Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells |
title_full | Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells |
title_fullStr | Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells |
title_full_unstemmed | Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells |
title_short | Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells |
title_sort | novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8096095/ https://www.ncbi.nlm.nih.gov/pubmed/33945569 http://dx.doi.org/10.1371/journal.pone.0250649 |
work_keys_str_mv | AT willifordsarahe noveldopaminereceptor3antagonistsinhibitthegrowthofprimaryandtemozolomideresistantglioblastomacells AT libbycatherinej noveldopaminereceptor3antagonistsinhibitthegrowthofprimaryandtemozolomideresistantglioblastomacells AT ayokanmbiadetokunbo noveldopaminereceptor3antagonistsinhibitthegrowthofprimaryandtemozolomideresistantglioblastomacells AT otamiasarphaxad noveldopaminereceptor3antagonistsinhibitthegrowthofprimaryandtemozolomideresistantglioblastomacells AT gordillojuanj noveldopaminereceptor3antagonistsinhibitthegrowthofprimaryandtemozolomideresistantglioblastomacells AT gordonemilyr noveldopaminereceptor3antagonistsinhibitthegrowthofprimaryandtemozolomideresistantglioblastomacells AT coopersaraj noveldopaminereceptor3antagonistsinhibitthegrowthofprimaryandtemozolomideresistantglioblastomacells AT redmannmatthew noveldopaminereceptor3antagonistsinhibitthegrowthofprimaryandtemozolomideresistantglioblastomacells AT liyanjie noveldopaminereceptor3antagonistsinhibitthegrowthofprimaryandtemozolomideresistantglioblastomacells AT griguercorinne noveldopaminereceptor3antagonistsinhibitthegrowthofprimaryandtemozolomideresistantglioblastomacells AT zhangjianhua noveldopaminereceptor3antagonistsinhibitthegrowthofprimaryandtemozolomideresistantglioblastomacells AT napieralamarek noveldopaminereceptor3antagonistsinhibitthegrowthofprimaryandtemozolomideresistantglioblastomacells AT ananthansubramaniam noveldopaminereceptor3antagonistsinhibitthegrowthofprimaryandtemozolomideresistantglioblastomacells AT hjelmelandanitab noveldopaminereceptor3antagonistsinhibitthegrowthofprimaryandtemozolomideresistantglioblastomacells |